NASDAQ:BIOS BioPlus Acquisition (BIOS) Stock Forecast, Price & News $10.83 -0.01 (-0.09%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$10.83▼$10.8350-Day Range$10.65▼$10.8452-Week Range$10.05▼$11.68Volume327 shsAverage Volume126,249 shsMarket Capitalization$209.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About BioPlus Acquisition (NASDAQ:BIOS) StockBioPlus Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. BioPlus Acquisition Corp. was incorporated in 2021 and is based in New York, New York.Read More BIOS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOS Stock News HeadlinesAugust 16, 2023 | finance.yahoo.comHeart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient MonitoringAugust 16, 2023 | finance.yahoo.comAvertix Partners with Institute on Implantable Heart Attack Detection SystemSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJuly 20, 2023 | finance.yahoo.comAvertix Medical Welcomes Renown Cardiologist to Board of DirectorsJuly 17, 2023 | finance.yahoo.comRenown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of DirectorsJune 13, 2023 | finance.yahoo.comAvertix’s Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth OrlandoMay 26, 2023 | seekingalpha.comBIOS BioPlus Acquisition Corp.May 5, 2023 | msn.comSPAC BIOS to merge with cardiac device maker AvertixSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsMay 3, 2023 | finance.yahoo.comAvertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition CorporationMarch 18, 2023 | money.usnews.comBioPlus Acquisition Corp - Ordinary Shares - Class ASeptember 23, 2022 | wsj.comBioPlus Acquisition Corp. Cl ASeptember 20, 2022 | finance.yahoo.comBioPlus Acquisition Corp. (BIOS)September 3, 2022 | investing.comBioPlus Acquisition Corp (BIOS)August 13, 2022 | reuters.comBioPlus Acquisition CorpAugust 10, 2022 | finance.yahoo.comWhat Type Of Shareholders Own The Most Number of BioPlus Acquisition Corp. (NASDAQ:BIOS) Shares?See More Headlines Receive BIOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPlus Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOS Company Calendar Today9/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Holding & other investment offices Sub-IndustryN/A SectorUnclassified Current SymbolNASDAQ:BIOS CUSIPN/A CIK1856653 Webbioplusspac.com Phone212-287-4092FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares19,370,000Free Float14,990,000Market Cap$209.78 million OptionableNot Optionable Beta0.02 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Jonathan M. N. Rigby MBA (Age 55)Chairman & Chief Bus. Officer Mr. R. Ross Haghighat (Age 59)CEO, CFO & Director Key CompetitorsJupiter AcquisitionNASDAQ:JAQCIntegrated Rail and Resources AcquisitionNYSE:IRRXCC Neuberger Principal Holdings IIINYSE:PRPCRCF AcquisitionNYSE:RCFABattery Future AcquisitionNYSE:BFACView All CompetitorsInstitutional OwnershipWestchester Capital Management LLCBought 83,406 shares on 8/15/2023Ownership: 4.742%Quarry LPBought 455,000 shares on 8/15/2023Ownership: 1.552%Hudson Bay Capital Management LPBought 200,000 shares on 8/15/2023Ownership: 1.535%Walleye Capital LLCBought 309,897 shares on 8/15/2023Ownership: 1.275%Walleye Trading LLCBought 146,197 shares on 8/15/2023Ownership: 0.622%View All Institutional Transactions BIOS Stock - Frequently Asked Questions How have BIOS shares performed in 2023? BioPlus Acquisition's stock was trading at $10.22 on January 1st, 2023. Since then, BIOS stock has increased by 6.0% and is now trading at $10.83. View the best growth stocks for 2023 here. Are investors shorting BioPlus Acquisition? BioPlus Acquisition saw a decline in short interest in September. As of September 15th, there was short interest totaling 1,600 shares, a decline of 36.0% from the August 31st total of 2,500 shares. Based on an average daily trading volume, of 40,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the company's shares are short sold. View BioPlus Acquisition's Short Interest. What ETF holds BioPlus Acquisition's stock ? CrossingBridge Pre-Merger SPAC ETF holds 29,741 shares of BIOS stock, representing 0.48% of its portfolio. When did BioPlus Acquisition IPO? (BIOS) raised $180 million in an IPO on Friday, December 3rd 2021. The company issued 18,000,000 shares at a price of $10.00 per share. Cantor acted as the underwriter for the IPO. What is BioPlus Acquisition's stock symbol? BioPlus Acquisition trades on the NASDAQ under the ticker symbol "BIOS." Who are BioPlus Acquisition's major shareholders? BioPlus Acquisition's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Westchester Capital Management LLC (4.74%), Mizuho Securities USA LLC (3.46%), Radcliffe Capital Management L.P. (2.45%), Berkley W R Corp (2.04%), Wolverine Asset Management LLC (1.65%) and Quarry LP (1.55%). How do I buy shares of BioPlus Acquisition? Shares of BIOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioPlus Acquisition's stock price today? One share of BIOS stock can currently be purchased for approximately $10.83. How much money does BioPlus Acquisition make? BioPlus Acquisition (NASDAQ:BIOS) has a market capitalization of $209.78 million. How can I contact BioPlus Acquisition? BioPlus Acquisition's mailing address is 260 MADISON AVENUE SUITE 800, NEW YORK NY, 10016. The official website for the company is bioplusspac.com. The company can be reached via phone at 212-287-4092. This page (NASDAQ:BIOS) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPlus Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.